Imatinib has EMA approval for the treatment of KIT-positive GISTs (in both adjuvant and metastatic settings), inoperable dermatofibrosarcoma protuberans, and chronic myeloid leukaemia (CML). Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.